4-(4-chlorophenyl)-5-(4-piperidinyl)-3-isoxazolol hydrobromide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(4-chlorophenyl)-5-(4-piperidinyl)-3-isoxazolol hydrobromide
• 英文别名: 4-(4-Chlorophenyl)-5-piperidin-4-yl-1,2-oxazol-3-one;hydrobromide
• 化学式: BrH*C₁₄H₁₅ClN₂O₂
• 分子量: 359.65
• InChiKey: AGOFZVVLZCXEMV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.33
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  50.4
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  3-benzyloxy-4-iodo-5-(1-methoxycarbonyl-4-piperidyl)isoxazol 在 bis-triphenylphosphine-palladium(II) chloride 、 氢溴酸 、 potassium carbonate 、 溶剂黄146 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 46.0h， 生成 4-(4-chlorophenyl)-5-(4-piperidinyl)-3-isoxazolol hydrobromide
  参考文献：
  名称：

  4-Aryl-5-(4-Piperidyl)-3-Isoxazolol GABA_A Antagonists:  Synthesis, Pharmacology, and Structure−Activity Relationships

  摘要：

  A series of 4-aryl-5-(4-piperidyl)-3-isoxazolol GABA(A) antagonists have been synthesized and pharmacologically characterized. The meta-phenyl-substituted compounds 9k and 9m and the para-phenoxy-substituted compound 9l all display high affinities (K-i = 10-70 nM) and antagonist potencies in the low nanomolar range (K-i = 9-10 nM). These potencies are significantly higher than those of previously reported 4-PIOL antagonists and considerably higher than that of the standard GABA(A) antagonist SR 95531.

  DOI：

  10.1021/jm070038n

文献信息

• 4-Aryl-5-(4-Piperidyl)-3-Isoxazolol GABA_A Antagonists:  Synthesis, Pharmacology, and Structure−Activity Relationships
  作者：Bente Frølund、Lars S. Jensen、Signe I. Storustovu、Tine B. Stensbøl、Bjarke Ebert、Jan Kehler、Povl Krogsgaard-Larsen、Tommy Liljefors

  DOI：10.1021/jm070038n

  日期：2007.4.1

  A series of 4-aryl-5-(4-piperidyl)-3-isoxazolol GABA(A) antagonists have been synthesized and pharmacologically characterized. The meta-phenyl-substituted compounds 9k and 9m and the para-phenoxy-substituted compound 9l all display high affinities (K-i = 10-70 nM) and antagonist potencies in the low nanomolar range (K-i = 9-10 nM). These potencies are significantly higher than those of previously reported 4-PIOL antagonists and considerably higher than that of the standard GABA(A) antagonist SR 95531.